Arvinas Inc
ARVNHealthcare|Biotechnology|USA
$8.28
-0.27 (-3.10%)
Tangible Book
$6.00
Upcoming Data Readouts (7)
Sep 2026
Est. completion
P1P2Breast Cancer
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
NCT05548127n=37
Dec 2026
Est. completion
P1Healthy Participants
A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function
NCT07231991n=24
Dec 2026
Est. completion
P1P2Breast Cancer
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
NCT05573555n=20
Dec 2026
Est. completion
P3Breast Cancer
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
NCT05909397n=59
Dec 2026
Est. completion
P1P2Breast Cancer
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)
NCT06125522n=11
Nov 2027
Est. completion
P1P2KRAS G12D Mutation
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
NCT07023731n=159
Mar 2028
Est. completion
P1Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
NCT06393738n=255
Awaiting Results (3)
Trials past primary completion date but still active — data readout may be imminent.
Sep 2025
P1P2
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
NCT06206837Jan 2025
P3
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623May 2023
P1
A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)
NCT05463952